Showing results (2281-2290 of 2,596) with videos related to
Sort By:
Pageof 260
Molecular Psychiatry|March 23, 2019
The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's diseaseNicolai Franzmeier, Jinyi Ren, Alexander Damm, et al.Nature|September 17, 2004
The DNA sequence and comparative analysis of human chromosome 5Jeremy Schmutz, Joel Martin, Astrid Terry, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stageNelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 23, 2025
Clinical use and reporting of neurofilament quantification in neurological disorders: A global overviewConstance Delaby, Aurélie Ladang, Jose Martinez-Yriarte, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersConstance Delaby, Aurélie Ladang, Jose Yriarte, et al.The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.Science Advances|July 3, 2024
Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy responseBrooke A Pereira, Shona Ritchie, Cecilia R Chambers, et al.Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.Brain : a Journal of Neurology|August 14, 2025
Connectivity as a universal predictor of tau progression in atypical Alzheimer's diseaseHannah de Bruin, Colin Groot, Henryk Barthel, et al.Pageof 260